Protective efficiency comparison of direct and remote ischemic preconditioning on ischemia reperfusion injury of liver in patients undergoing subtotal hepatectomy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200064608

Enrollment

Unknown

Registered

2022-10-12

Start date

2022-10-12

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemia reperfusion injury of liver

Interventions

Control Group:No

DIPC Group:Direct transient ischemic preconditioning of the liver

RIPC Group:Transient ischemic preconditioning of the right upper limb

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-80; 2. The ASA classification is II-III; 3. Child-Pugh classification of liver function was A-B; 4. First liver surgery; 5. Use general anesthesia; 6. Right liver tumor, tumor size <10 cm; 7. The operation was a standard hepatectomy with a resection scope of more than 50%, and Pringle's method was used to block the hepatic portal vein during the operation.

Exclusion criteria

Exclusion criteria: 1. Peripheral vascular disease affecting upper limb function; 2. Severe liver cirrhosis; 3. The surgical procedure was different from the predicted method; 4. Previous history of liver surgery; 5. The hepatic portal vein was not blocked during the operation or the cumulative blocking time was more than 60 minutes; 6. Blood loss > 4000 ml; 7. Combined with other major organ system diseases, such as heart infarction, chronic obstructive pulmonary disease, and cerebral infarction; 8. Preoperative cardiopulmonary, renal function and electrolytes were significantly abnormal; 9. Diabetic patients taking glyburide and sulfonylureas; 10. Intraoperative use of glucocorticoids and other anti-inflammatory drugs; 11. History of endocrine diseases and opioid addiction; 12. Previous history of liver intervention, radiofrequency, radiotherapy and chemotherapy; 13. Combined with mental illness, lung infection, etc.

Design outcomes

Primary

Measure	Time frame
Indolicide green plasma clearance rate;15 min retention rate of indole green;Effective hepatic blood flow;	—

Secondary

Measure	Time frame
ALT;AST;TBIL;	—

Countries

China

Contacts

Public ContactErliang Kong

The 988th Hospital of Joint Logistic Support Force of Chinese People’s Liberation Army

kel1992@126.com+86 13917506501

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026